相关实验视频

Updated: Jul 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

安德罗格里斯通过miR-155-5p/SIRT1轴调节肺癌中西斯普拉丁耐药性的作用

Chong Pang¹, Tengyue Zhang², Yulong Chen¹

¹Department of Lung Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin, China.

Functional & integrative genomics

|August 2, 2023

概括

安德罗格里斯 (Andro) 通过向miR-155-5p/SIRT1通路来对抗肺癌中西斯普拉丁耐药性. 这种草药化合物提高了化疗的有效性,并降低了癌细胞的活力.

科学领域:

药理学药理学是指药理学的学科.
分子生物学分子生物学
在瘤学瘤学.

背景情况:

对西斯普拉丁的耐药性是肺癌治疗的一个主要挑战.
安德罗格里斯 (Andrographis) (安德罗) 具有抗癌性质.
了解安德罗在抗西斯普拉丁耐药性的调节机制至关重要.

研究的目的:

研究Andrographis (Andro) 的调节途径,以克服肺癌中对西斯 (DDP) 的耐药性.
为了阐明miR-155-5p/SIRT1轴在Andro的抗癌作用中的作用.

主要方法:

细胞活力测试 (CCK8) 和亡分析是在肺癌细胞上进行的.
用RT-qPCR和西部斑点来评估miR-155-5p和SIRT1的表达.
路西法酶记者测定证实了SIRT1和miR-155-5p之间的相互作用.
异种移植模型被用于体内验证.

主要成果:

安德罗降低了肺癌细胞的活力,而不会影响正常细胞.
联合Andro和DDP治疗显著降低了生命力和增加了细胞亡.
安德罗抑制了miR-155-5p,并促进了SIRT1的表达,这种关系被证实是直接的目标相互作用.
在体内研究表明,Andro通过miR-155-5p/SIRT1通路与DDP的协同作用.

结论:

安德罗格里斯 (Andro) 有效调节肺癌中西斯的耐药性.
miR-155-5p/SIRT1轴是Andro作用的关键调节途径.
安德罗具有作为辅助疗法的潜力,可以增强西斯在肺癌治疗中的疗效.

关键词:

安德罗克拉菲斯 (Andrographis) 是一种化疗化疗是一种化学疗法.西斯普拉丁 (Cisplatin) 是一种草本草药是一种草药.一个SIRT1系统.

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...